Lamivudine Therapy Exacerbates Bilirubinemia in Patients Underlying Severely Advanced Hepatitis-Reference-Cited by-同舟云学术

Lamivudine Therapy Exacerbates Bilirubinemia in Patients Underlying Severely Advanced Hepatitis

Published:2017-10-15 Issue:4 Volume:33 Page:343-350
ISSN:1976-8257
Container-title:Toxicological Research
language:en
Short-container-title:ToxicolRes

Author:

Choi Young Hee¹,Lee Chang Ho²,Ko Myong Suk³,Han Hyun Joo⁴,Kim Sang Geon⁴⁵

Affiliation:

1. College of Pharmacy, Dongguk University_Seoul, Seoul, Korea

2. Department of Pharmacology, College of Medicine, Hanyang University, Seoul, Korea

3. Korea Intellectual Property Strategy Agency, Business Cooperation Team, Seoul, Korea

4. Department of Pharmacy, Seoul National University Hospital, Seoul, Korea

5. College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea

Funder

Seoul National University Hospital(SNUH)

Publisher

The Korean Society of Toxicology

Subject

Health, Toxicology and Mutagenesis,Toxicology

Link

http://pdf.medrang.co.kr/TR/2017/033/TR033-04-10.pdf

Reference34 articles.

1. Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation

2. Andreea, F, and Marius, B (2009). Adverse drug reactions in clinical practice: a causality assessment of a case of drug-induced pancreatitis. J Gastrointest Liver Dis. 18, 353-358.

3. Identifying Adverse Drug Events: Development of a Computer-based Monitor and Comparison with Chart Review and Stimulated Voluntary Report

4. Kohn, LT, Corrgan, JM, and Donaldson, MS (1999). To Err in Human: Building a Safer Health System. Washington, D.C: National Academy Press

5. Lee, YH, Kang, UG, and Park, RW (2008). Development of adverse drug event surveillance system using BI technology. Int J Contents. 9, 106-113.